ALK and non-small cell lung carcinoma: Other clinical studies on NSCLC reported that epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) rearrangements, KRAS, and BRAF do not influence the efficacy of the immune checkpoint inhibitor [261,262,263].